Suppr超能文献

18F-FDG PET/CT的最大标准摄取值、代谢肿瘤体积和总病变糖酵解对肾癌患者的预后价值:一项系统评价和荟萃分析方案

Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma: A protocol for systematic review and meta analysis.

作者信息

Xuan Dongchun, Wen Weibo, Tian Shengri, Piao Minhu, Xu Dongyuan, Liu Lan

机构信息

Center of Morphological Experiment, Medical College of Yanbian University.

Department of Nuclear Medicine.

出版信息

Medicine (Baltimore). 2020 May;99(20):e19988. doi: 10.1097/MD.0000000000019988.

Abstract

PURPOSE

We present a comprehensive systematic review of the documented literature on parameters derived from F-fluorodeoxyglucose positron emission tomography (F-FDG PET) and meta-analysis of the prognostic value of maximal standard uptake value (SUVmax), metabolic tumor volume (MTV) and total lesional glycolysis (TLG) in patients with renal carcinoma (RCC).

PATIENTS AND METHODS

Relevant articles in English from PubMed, EMBASE, and the Cochrane Library were retrieved. Pooled hazard ratio (HR) values were used to assess the prognostic value of SUVmax, MTV, and TLG.

RESULTS

A total of 10 primary studies involving 780 patients with RCC were included. The combined HRs for event-free survival were 1.32 (95% CI 1.10-1.58) for SUVmax, 2.40 (95% CI 1.20-4.79) for MTV, and 3.31 (95% CI 1.68-6.50) for TLG. Pooled HRs for overall survival were 1.264 (95% CI 1.124-1.421) for SUVmax, 3.52 (95% CI 1.451-8.536) for MTV, and 6.33 (95% CI 1.32-30.30) for TLG. Subgroup analysis revealed SUVmax as an independent risk factor for patients with recurrence or metastasis.

CONCLUSION

The present meta-analysis confirmed that despite the clinical heterogeneity of RCC and adoption of various methods between studies, high SUVmax is a significant prognostic factor, especially in patients with recurrence or metastasis. MTV and TLG were associated with prediction of higher risk of adverse events or death in patients with RCC.

摘要

目的

我们对源自氟脱氧葡萄糖正电子发射断层扫描(F-FDG PET)的参数的文献进行了全面的系统评价,并对最大标准摄取值(SUVmax)、代谢肿瘤体积(MTV)和总病变糖酵解(TLG)在肾癌(RCC)患者中的预后价值进行了荟萃分析。

患者与方法

检索了PubMed、EMBASE和Cochrane图书馆中用英文发表的相关文章。采用合并风险比(HR)值评估SUVmax、MTV和TLG的预后价值。

结果

共纳入10项涉及780例RCC患者的初步研究。SUVmax的无事件生存合并HR为1.32(95%CI 1.10-1.58),MTV为2.40(95%CI 1.20-4.79),TLG为3.31(95%CI 1.68-6.50)。SUVmax的总生存合并HR为1.264(95%CI 1.124-1.421),MTV为3.52(95%CI 1.451-8.536),TLG为6.33(95%CI 1.32-30.30)。亚组分析显示SUVmax是复发或转移患者的独立危险因素。

结论

本荟萃分析证实,尽管RCC存在临床异质性且各研究采用的方法不同,但高SUVmax是一个重要的预后因素,尤其是在复发或转移患者中。MTV和TLG与RCC患者不良事件或死亡风险较高的预测相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a0e/7254885/2d7800ba856c/medi-99-e19988-g003.jpg

相似文献

7
Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients.
Medicine (Baltimore). 2017 Apr;96(17):e6721. doi: 10.1097/MD.0000000000006721.
8
The correlation of F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.
Clin Transl Oncol. 2021 Mar;23(3):620-627. doi: 10.1007/s12094-020-02457-w. Epub 2020 Jul 18.
9
Prognostic prediction by F-FDG-PET/CT parameters in patients with neuroblastoma: a systematic review and meta-analysis.
Front Oncol. 2023 Jul 14;13:1208531. doi: 10.3389/fonc.2023.1208531. eCollection 2023.

引用本文的文献

1
The Utility of F-FDG PET/CT in Detecting Multiple Metastases in Papillary Renal Cell Carcinoma.
Mol Imaging Radionucl Ther. 2025 Feb 7;34(1):64-65. doi: 10.4274/mirt.galenos.2024.02259.
3
Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.
Front Med (Lausanne). 2021 Nov 26;8:771912. doi: 10.3389/fmed.2021.771912. eCollection 2021.

本文引用的文献

1
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Curr Urol Rep. 2019 Aug 29;20(10):56. doi: 10.1007/s11934-019-0932-2.
2
FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma.
Clin Exp Med. 2019 Feb;19(1):143-148. doi: 10.1007/s10238-018-0539-9. Epub 2018 Nov 28.
3
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Cancer Chemother Pharmacol. 2018 Apr;81(4):739-744. doi: 10.1007/s00280-018-3542-7. Epub 2018 Feb 20.
4
Recent developments in small molecule therapies for renal cell carcinoma.
Eur J Med Chem. 2017 Dec 15;142:383-392. doi: 10.1016/j.ejmech.2017.08.007. Epub 2017 Aug 9.
5
Current management of metastatic renal cell carcinoma: evolving new therapies.
Curr Opin Support Palliat Care. 2017 Sep;11(3):231-237. doi: 10.1097/SPC.0000000000000277.
7
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Cancer Chemother Pharmacol. 2017 May;79(5):855-861. doi: 10.1007/s00280-017-3275-z. Epub 2017 Mar 22.
10
Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer.
PLoS One. 2016 Oct 31;11(10):e0165814. doi: 10.1371/journal.pone.0165814. eCollection 2016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验